MURPHY ERIC A (US)
MATSUZAKI HAJIME (US)
MURPHY ERIC A (US)
| WO1996001909A1 | 1996-01-25 | |||
| WO1996010648A2 | 1996-04-11 | |||
| WO1996039535A1 | 1996-12-12 | |||
| WO1996041012A1 | 1996-12-19 |
| EP0648845A2 | 1995-04-19 |
| 1. | A method of performing multiple polymerase chain reactions in a single vessel, comprising: priming DNA synthesis on a template in a vessel with at least two sets of primers, wherein the primers are present in the vessel at a predetermined ratio, wherein the ratio is described by: CA =CL (LA#LL)2 wherein CA is the concentration of primers for an amplicon A; wherein CL is the concentration of primer for the longest amplicon; wherein LA is the length of the amplicon A; and wherein LL is the length of the longest amplicon. |
| 2. | The method of claim 1 wherein the template is genomic DNA encoding p53. |
| 3. | The method of claim 1 wherein the template is a cDNA encoding p53. |
| 4. | The method of claim 1 wherein the primers amplify at least 2 exons of p53 selected from the group consisting of exons 211. |
| 5. | The method of claim 1 wherein the primers amplify at least 4 exons of p53 selected from the group consisting of exons 211. |
| 6. | The method of claim 1 wherein the primers amplify exons 211 of p53. |
| 7. | The method of claim 4 wherein the primers are selected from those shown in SEQIDNO: IDNOS: 120. |
| 8. | The method of claim 5 wherein the primers are selected from those shown in SEQIDNO: IDNOS: 120. |
| 9. | The method ofclaim 6 wherein the primers are shown in SEQ ID NO: ID NOS: 120. |
| 10. | The method of claim 9 wherein the primers are present in the following ratios: exon 2 (89.4): exon 3 (26.9): exon 4 (450): exon 5 (245.8): exon 6 (138.3): exon 7 (101.8): exon 8 (193.0): exon 9 (70.8): exon 10 (146.5): exon 11 (177.3). |
| 11. | A method of performing multiple polymerase chain reactions in a single vessel, comprising: priming DNA synthesis on a genomic p53 template in a vessel with ten sets of primers which amplify exons 211 of p53, wherein the primers are shown in SEQ ID NOS: 120, wherein the primers are present in the vessel at the following ratios: exon 2 (89.4), exon 3 (26.9), exon 4 (450), exon 5 (245.8), exon 6 (138.3), exon 7 (101.8), exon 8 (193.0), exon 9 (70.8), exon 10 (146.5), exon 11 (177.3). |
| 12. | A kit comprising a set of primers for performing multiple polymerase chain reactions in a single vessel, comprising: twenty primers having sequences as shown in SEQ ID NO: ID NOS: 1 20. |
| 13. | The kit of claim 12 wherein the ratio of the concentrations of the primers is described by: CA =CL OLA : wherein CA is the concentration of primers for an amplicon A; wherein C L is the concentration of primer for the longest amplicon; wherein LA is the length of the amplicon A; and wherein LL is the length of the longest amplicon. |
| 14. | The kit of claim 12 wherein the ratio of the primers is: exon 2 (89.4): exon 3 (26.9): exon 4 (450): exon 5 (245.8): exon 6 (138.3): exon 7 (101.8): exon 8 (193.0): exon 9 (70.8): exon 10 (146.5): exon 11 (177.3). |
| 15. | A mixture of primers for performing multiplex polymerase chain reaction, wherein the primers are present in the mixture at a predetermined ratio to each other, wherein the ratio of the concentrations of the primers is described by: CA =CL (LA : LL)2 wherein CA is the concentration of primers for an amplicon A; wherein CL is the concentration of primer for the longest amplicon; wherein LA is the length of the amplicon A; and wherein LL is the length of the longest amplicon. |
| 16. | The mixture of claim 15 which comprises at least 4 primers. |
| 17. | The mixture of claim 15 which comprises at least 6 primers. |
| 18. | The mixture of claim 15 which comprises at least 8 primers. |
| 19. | The mixture of claim 15 which comprises at least 10 primers. |
| 20. | The mixture of claim 15 which comprises at least 12 primers. |
| 21. | The mixture of claim 15 which comprises at least 14 primers. |
| 22. | The mixture of claim 15 which comprises at least 16 primers. |
| 23. | The mixture of claim 15 which comprises at least 18 primers. |
| 24. | The mixture of claim 15 which comprises at least 20 primers. |
60/050,405, filed on June 20, 1997, the text of which is expressly incorporated herein, BACKGROUND OF THE INVENTION The polymerase chain reaction (PCR) is a simple and versatile method to amplify in vitro a specific segment of DNA for subsequent study (Saiki et al., Science 230:1350 (1985); Saiki et al., Science 25:487 (1985)). The PCR method has gained widespread use in biomedical research, and has revolutionized the accurate and early diagnosis of many inherited and acquired genetic disorders (Eisenstein, N. Engl. J. Med. ,=: 178 (1990)), particularly those caused by point mutations or small insertions or deletions including sickle cell anemia (Saiki et al., Science 2iQ-.1350 (1985)), hemophilia A (Kogan et al., N. Engl. J. Med. 317:985 (1987)), Tay-Sach's disease (Myerowitz, Proc. Natl. Acad. Sci. USA g:3955 (1988); Myerowitz et al., J. Biol. Chem. =: 18587 (1988)), cystic fibrosis (Riordan et al., Science 2£2: 1066 (1989)), and many others. With PCR, it is also possible to detect heterozygotic carriers in recessive disorders.
Polymerase chain reaction (PCR) is used for a variety of purposes. PCR can be used to amplify genomic DNA or other sources of nucleic acids for analysis. It is often desirable to be able to achieve equimolar yields of different length amplicons when performing multiplex PCR or multiple PCR reactions. Having an approximately equimolar yield of amplicons is particularly useful, for example, when approximately equal representation of certain regions of genomic DNA amplified after multiplex PCR is desired. Prior to the methods of present invention, finding the appropriate experimental conditions useful to achieve this result has been difficult because PCR amplifies nucleic acids having different lengths with different efficiencies. The yield of longer amplicons is often less than the yield of shorter amplicons because of those differences in PCR amplification efficiency. Figure 1 shows the difference in yields that one might expect, for example, when starting with equal primer concentrations used to amplify amplicons of varying lengths: A, B, C.
There is a continuing need in the art for methods which permit the amplification of different sequences with the same efficiency so that approximately equimolar products result.
SUMMARY OF THE INVENTION It is an object of the present invention to provide a method of performing multiplex PCR which achieve approximately equimolar products.
It is another object of the invention to provide a set of primers for amplification ofp53.
It is yet another object of the invention to provide a set of primers for amplification of p53 to achieve approximately equimolar products.
It is still another object of the invention to provide a mixture of primers for
performing multiplex PCR.
These and other objects of the invention are provided by one or more of the embodiments provided below. In one embodiment of the invention a method of performing multiple polymerase chain reactions in a single vessel is provided. The method comprises the steps of priming DNA synthesis on a template in a vessel with at least two sets of primers. The primers are present in the vessel at a predetermined ratio which is described by the formula: CA =CL (LA -: CA is the concentration of primers for an amplicon A. CL is the concentration of primer for the longest amplicon. LA is the length of the amplicon A. LL is the length of the longest amplicon.
Another embodiment provided by the invention is a method of performing multiple polymerase chain reactions in a single vessel. The method comprises priming DNA synthesis on a genomic p53 template in a vessel with ten sets of primers which amplify exons 2-11 ofp53. The primers are shown in SEQ ID NO: ID NOS: 1-20. The primers are present in the vessel at the following ratio: exon 2 (89.4): exon 3 (26.9): exon4 (450): exon5(245.8): exon 6(138.3): exon 7(101.8): exon 8(193.0): exon 9 (70.8): exon 10 (146.5): exon 11(177.3).
According to still another embodiment of the invention a set of primers for performing multiple polymerase chain reactions in a single vessel is provided. The set comprises twenty primers having sequences as shown in SEQ ID NO: 1-20.
According to yet another embodiment of the invention a mixture of primers for performing multiplex polymerase chain reaction is provided. The primers are present in the mixture at a predetermined ratio to each other. The ratio of the concentrations of
the primers is described by: CA =CL (LA#LL)2 wherein CA is the concentration of primers for an amplicon A; wherein CL is the concentration of primer for the longest amplicon; wherein LA is the length of the amplicon A; and wherein LL is the length of the longest amplicon.
The present invention thus provides the art with a method useful for performing multiplex PCR This method is particularly useful for amplification of multiple exons of p53. Moreover, a particular primer set useful for performing such multiplex PCR is also provided.
BRIEF DESCRIPTION OF THE DRAWINGS Figure 1 shows the difference in yields that one might expect, for example, when starting with equal primer concentrations used to amplify amplicons of varying lengths: A, B, C.
Figure 2 illustrates the relationship for given values X and LL, using the amplicons from different exons of the human p53 gene as an example.
DETAILED DESCRIPTION OF THE INVENTION It is a discovery ofthe present invention that approximately equimolar yields of amplicons of varying lengths can be easily produced by multiplex PCR. It has been determined that varying the primer concentrations as a function of the lengths of amplicons yields approximately equimolar amounts of amplicons of varying lengths. The relationship between primer concentration and the length of amplicons is as follows: CA=CL( LA/LL)X
wherein CA = the concentration of primers for an amplicon A; CL = the concentration of primer for the longest amplicon; LA = the length of amplicon A; LL = the length ofthe longest amplicon; and X is usually not zero and is often between one and three.
This relationship can be placed in a computer readable medium or be used with a computer system if desired.
Figure 2 illustrates the relationship for given values X and LL, using the amplicons from different exons of the human p53 gene as an example. Using primer concentrations as set forth, for example in Figure 2, one skilled in the art can determine the optimum set of primer concentrations to yield approximately equimolar yields of varying length amplicons in a multiplex or multiple PCR. Preferably, primers having both comparable base composition and comparable melting temperatures are used. Also preferably, Mg+2 concentration, annealing temperatures, and cycling times of the PCR are optimized prior to choosing the desired set of primer concentrations in accordance with the present invention.
PCR techniques applicable to the present invention include inter alia those discussed inPCRPRIMER: ALABoRAIDRYMANUAL, Dieffenbach, C.W. and Dveksler, G.S., eds., Cold Spring Harbor Laboratory Press (1995).
The present application further provides primer sequences, primer concentrations, and experimental conditions useful in the amplification of the coding region ofthe human p53 gene. Particularly useful primers for amplification of exons of the p53 gene are set forth in Table 1.
TABLE 1 p53 Primer Set 20 primers in 1 mM Tris-HC1, pH 7.4, 0.1 mM EDTA, sequences: Exon 2: 5'-TCATGCTGGATCCCCACTTTTCCTCTTG-3' S'TGGCCTGCCCTTCCAATGGATCCACTCA-3' Exon 3: 5'-AATTCATGGGACTGACTTTCTGCTCTTGTC-3' 5'-TCCAGGTCCCAGCCCAACCCTTGTCC-3' Exon 4: 5'-GTCCTCTGACTGCTCTTTTCACCCATCTAC-3' 5'-GGGATACGGCCAGGCATTGAAGTCTC-3' Exon 5: 5'-CTTGTGCCCTGACTTTCAACTCTGTCTC-3' 5'-TGGGCAACCAGCCCTGTCGTCTCTCCA-3' Exon 6: 5'-CCAGGCCTCTGATTCCTCACTGATTGCTC-3' 5'-GCCACTGACAACCACCCTTAACCCCTC-3' Exon 7: 5'-GCCTCATCTTGGGCCTGTGTTATCTCC-3' 5'-GGCCAGTGTGCAGGGTGGCAAGTGGCTC-3' Exon 8: 5 '-GTAGGACCTGATTTCCTTACTGCCTCTTGC-3 5'-ATAACTGCACCCTTGGTCTCCTCCACCGC-3' Exon 9: 5'-CACTTTTATCACCTTTCCTTGCCTCTTTCC-3' 5'-AACTTTCCACTTGATAAGAGGTCCCAAGAC-3' Exon 10: 5'-ACTTACTTCTCCCCCTCCTCTGTTGCTGC-3' 5'-ATGGAATCCTATGGCTTTCCAACCTAGGAAG-3' Exon 11: 5'-CATCTCTCCTCCCTGCTTCTGTCTCCTAC-3' 5'-CTGACGCACACCTATTGCAAGCAAGGGTTC-3' Table 2 shows particularly useful concentrations of the primers set forth in Table 1 for multiplex PCR amplification using the experimental conditions set forth in Table 3.
TABLE 2 Primer Concentrations in p53 Primer Set Values of Typical values of X2 CLAM Longest Shortest Amplicon Length Primer Concs 4 368 bp 450.0 nM 5 272 bp 245.8 nM 8 241 bp 193.0 nM 11 231 bp 177.3 nM 10 210 bp 146.5 nM 6 204 bp 138.3 nM 7 175 bp 101.8 nM 2 164 bp 89.4 nM 9 146 bp 70.8 nM 3 90 bp 26.9 nM TABLE 3 Multiplex PCR Start with 250 ng of Template DNA.
PCR Components for 100 ul PCR in 0.2 ml thin walled tubes: - Stock Final Conc for 1 reaction Conc Buffer (No Mg) 10 X 1 X 10.0 ul MgC12 | 25 mM 2.5 mM 10.0 ul dATP 10 mM 200 uM 2.0 ul dCTP 10 mM 200 uM 2.0 ul dGTP 10 mM 200 uM 2.0 ul dTTP l0mM 200 uM 2.0 ul Taq GOLD 5 U/ul 10 U 2.0 ul p53 Primer Set 20 X 1 X 5.0 ul Water Human genomic 250 ng DNA Total Volume 100.0 ul Final Concentations in Buffer (No Mg) are 10 mM Tris-HCl (pH 8.3), 50 mM KCl Taq GOLD is AmpliTaq GoldTM from Perkin Elmer catalog # N808-0243 PCR Cycles: 94 C 10 min 35 Cycles: 94 C 30 sec 60 C 30 sec 72 C 45 sec 72 C 10 min To visualize amplicons by gel Analysis: Visualize PCR products on 4% NuSieve Agarose Gel NuSieveTM Agarose 3:1 is from FMC catalog # 50092 Load 5 ul of PCR + loading buffer Use 50 bp Ladder (Gibco/BRLcatalog # 1041601,4) as size marker Run gel at 125 Volts for 30 min. to 90 min.
Expected PCR Products: Order in Gel: Amplicon Length Amplicon Length Exon 2 164 bp Exon 4 368 bp Exon 3 90 bp Exon 5 272 bp Exon 4 368 bp Exon 8 241 bp Exon 5 272 bp Exon 11 225 bp Exon 6 204 bp Exon 10 210 bp Exon 7 175 bp Exon 6 204 bp Exon 8 241 bp Exon 7 175 bp Exon 9 146 bp Exon 2 164 bp Exon 10 210 bp Exon 9 146 bp Exon 11 225 bp Exon 3 90 bp
Using the methods and reagents provided herein, we achieved multiplex PCR amplification of coding regions shown of the human p53 gene in approximately equimolar amounts. That desirable result was achieved in a single-tube reaction. The achievement of such desirable results with the remarkable convenience of a single tube reaction further illustrates the contribution to the art made by the present invention.
The methods and compositions ofthe present invention are useful in virtually any context in which equimolar yields of various PCR products are desired. Such contexts include without limitation paternity testing, forensic analysis, genetic screening, polymorphism detection, and mutation analyses. The present invention can be used to amplify nucleic acids for all forms of sequence analysis known to those skilled in the art.
Sequence analysis techniques includes, for example, dideoxy-sequencing and sequence analysis using high-density nucleic acid arrays: the GeneChipX probe arrays or VLSlPS technology of Ametrix, Inc. High density nucleic acid arrays are discussed for example in Chee, M., Yang, R, Hubbell, E., Berno, k, Huang, X.C., Stern, D., Winkler, J., Lockhart, D.J., Morris, M.S.,, & Fodor, S.P., Science 5287, 610-614 (1996), U.S. Patent No. 5,445,934, and International Publication No. WO 95/11995 corresponding to PCT Application No. PCT/US94/12305.
The p53 gene and its protein product are discussed in Molecular Biology of the Cell, 3rd Edition, Alberts, B., Bray, D., Lewis, J., Raff, M., Roberts, K., and Watson, J.D., Garland Publishing (1994) at pages 889 and 1284-1289.
It is understood that the examples and embodiments described herein are for illustrative purposes only and that various modifications or changes in light thereof will be suggested to persons skilled in the art and are to be included within the spirit and purview of this application and scope of any appended claims. All publications, patents, and patent applications cited herein are hereby incorporated by reference in their entirety for all purposes.
SEQUENCE LISTING (1) GENERAL INFORMATION (i) APPLICANT: MATSUZAKI, HAJIME (ii) TITLE OF THE INVENTION: METHODS AND COMPOSITIONS FOR MULTIPLEX AMPLIFICATION OF NUCLEIC ACIDS (ilk) NUMBER OF SEQUENCES: 20 (iv) CORRESPONDENCE ADDRESS: (A) ADDRESSEE: Banner & Witcoff (B) STREET: 1001 G Street, NW (C) CITY: Washington (D) STATE: DC (E) COUNTRY: USA (F) ZIP: 20001 (v) COMPUTER READABLE FORM: (A) MEDIUM TYPE: Diskette (B) COMPUTER: IBM Compatible (C) OPERATING SYSTEM: DOS (D) SOFTWARE: FastSEQ for Windows Version 2.0 (vi) CURRENT APPLICATION DATA: (A) APPLICATION NUMBER: (B) FILING DATE: 28-JUN-1998 (C) CLASSIFICATION: (viz) PRIOR APPLICATION DATA: (A) APPLICATION NUMBER: 60/050,405 (B) FILING DATE: 20-JUN-1997 (viii) ATTORNEY/AGENT INFORMATION: (A) NAME: Ragan, Sarah A (B) REGISTRATION NUMBER: 32141 (C) REFERENCE/DOCKET NUMBER: 03848.74891 (ix) TELECOMMUNICATION INFORMATION: (A) TELEPHONE: 202-508-9100 (B) TELEFAX: 202-508-9299 (C) TELEX: (2) INFORMATION FOR SEQ ID NO:1: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 28 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single
(D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1: TCATGCTGGA TCCCCACTTT TCCTCTTG 28 (2) INFORMATION FOR SEQ ID NO:2: (i) SEQUENCE CHARACTER STICS: (A) LENGTH: 28 base pairs.
(B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2: TGGCCTGCCC TTCCAATGGA TCCACTCA 28 (2) INFORMATION FOR SEQ ID NO:3: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 30 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:3: AATTCATGGG ACTGACTTTC TGCTCTTGTC 30 (2) INFORMATION FOR SEQ ID NO:4: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 26 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:4: TCCAGGTCCC AGCCCAACCC TTGTCC 26 (2) INFORMATION FOR SEQ ID NO:5: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 30 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5: GTCCTCTGAC TGCTCTTTTC ACCCATCTAC 30 (2) INFORMATION FOR SEQ ID NO:6: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 26 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:6: GGGATACGGC CAGGCATTGA AGTCTC 26 (2) INFORMATION FOR SEQ ID NO:7: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 28 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:7: CTTGTGCCCT GACTTTCAAC TCTGTCTC 28 (2) INFORMATION FOR SEQ ID NO:8: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 27 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:8: TGGGCAACCA GCCCTGTCGT CTCTCCA 27 (2) INFORMATION FOR SEQ ID NO:9: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 29 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9: CCAGGCCTCT GATTCCTCAC TGATTGCTC 29 (2) INFORMATION FOR SEQ ID NO:10: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 27 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:10: GCCACTGACA ACCACCCTTA ACCCCTC 27 (2) INFORMATION FOR SEQ ID NO:11: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 27 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:11: GCCTCATCTT GGGCCTGTGT TATCTCC 27 (2) INFORMATION FOR SEQ ID NO:12: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 28 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:12: GGCCAGTGTG CAGGGTGGCA AGTGGCTC 28 (2) INFORMATION FOR SEQ ID NO:13: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 30 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:
GTAGGACCTG ATTTCCTTAC TGCCTCTTGC 30 (2) INFORMATION FOR SEQ ID NO:14: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 29 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear.
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:14: ATAACTGCAC CCTTGGTCTC CTCCACCGC 29 (2) INFORMATION FOR SEQ ID NO:15: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 30 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:15: CACTTTTATC ACCTTTCCTT GCCTCTTTCC 30 (2) INFORMATION FOR SEQ ID NO:16: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 30 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:16: AACTTTCCAC TTGATAAGAG GTCCCAAGAC 30 (2) INFORMATION FOR SEQ ID NO:17: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 29 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:17: ACTTACTTCT CCCCCTCCTC TGTTGCTGC
29 (2) INFORMATION FOR SEQ ID NO:18: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 31 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:18: ATGGAATCCT ATGGCTTTCC AACCTAGGAA G 31 (2) INFORMATION FOR SEQ ID NO:19: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 29 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:19: CATCTCTCCT CCCTGCTTCT GTCTCCTAC 29 (2) INFORMATION FOR SEQ ID NO:20: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 30 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:20: CTGACGCACA CCTATTGCAA GCAAGGGTTC 30